76,729 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Bought by Lighthouse Investment Partners LLC

Lighthouse Investment Partners LLC bought a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTXFree Report) in the 4th quarter, HoldingsChannel reports. The fund bought 76,729 shares of the biopharmaceutical company’s stock, valued at approximately $1,311,000.

Several other institutional investors have also recently added to or reduced their stakes in TGTX. Pingora Partners LLC bought a new stake in TG Therapeutics during the fourth quarter valued at $27,000. PNC Financial Services Group Inc. increased its stake in TG Therapeutics by 131.7% during the third quarter. PNC Financial Services Group Inc. now owns 3,543 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 2,014 shares during the last quarter. Anchor Investment Management LLC bought a new stake in TG Therapeutics during the fourth quarter valued at $80,000. Sherbrooke Park Advisers LLC bought a new stake in TG Therapeutics during the third quarter valued at $104,000. Finally, Clark Financial Services Group Inc. BD increased its stake in TG Therapeutics by 15.1% during the third quarter. Clark Financial Services Group Inc. BD now owns 14,195 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 1,860 shares during the last quarter. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Stock Performance

NASDAQ:TGTX opened at $15.90 on Tuesday. TG Therapeutics, Inc. has a twelve month low of $6.46 and a twelve month high of $27.86. The company has a current ratio of 3.62, a quick ratio of 2.84 and a debt-to-equity ratio of 0.63. The company has a 50-day moving average of $15.62 and a 200-day moving average of $15.77. The firm has a market cap of $2.46 billion, a price-to-earnings ratio of 69.13 and a beta of 2.30.

TG Therapeutics (NASDAQ:TGTXGet Free Report) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02). TG Therapeutics had a return on equity of 31.34% and a net margin of 14.24%. The firm had revenue of $63.47 million during the quarter, compared to analyst estimates of $54.60 million. During the same quarter in the previous year, the business earned ($0.28) earnings per share. The business’s quarterly revenue was up 713.5% compared to the same quarter last year. Analysts forecast that TG Therapeutics, Inc. will post -0.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. The Goldman Sachs Group boosted their target price on shares of TG Therapeutics from $12.00 to $13.00 and gave the company a “neutral” rating in a research note on Thursday, February 29th. HC Wainwright boosted their price target on shares of TG Therapeutics from $45.00 to $49.00 and gave the company a “buy” rating in a report on Thursday, May 2nd. JPMorgan Chase & Co. reissued an “overweight” rating and set a $25.00 price target on shares of TG Therapeutics in a report on Thursday, April 18th. StockNews.com downgraded shares of TG Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 24th. Finally, LADENBURG THALM/SH SH boosted their price target on shares of TG Therapeutics from $39.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, May 2nd. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, TG Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $29.83.

Check Out Our Latest Analysis on TGTX

About TG Therapeutics

(Free Report)

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

Recommended Stories

Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc. (NASDAQ:TGTXFree Report).

Institutional Ownership by Quarter for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.